文献速递心脑血管急症重症综合管理与镇静镇痛

持续高渗治疗与创伤性脑损伤患者生存的关联:多中心前瞻性队列研究及系统评价

Association between continuous hyperosmolar therapy and survival in patients with traumatic brain injury - a multicentre prospective cohort study and systematic review.
PubMed 文献 · Crit Care · 2017-12-28
一句话结论在创伤性脑损伤合并颅内高压患者中,持续高渗治疗(20%氯化钠静脉输注≥24小时)与调整后90天生存改善相关(调整HR 1.74)。

本研究基于Corti-TC、BI-VILI和ATLANREA三项前瞻性多中心试验数据库,纳入格拉斯哥昏迷评分≤12且脑CT有创伤相关病灶的TBI患者1086例,其中545例(51.7%)发生颅内高压,143例接受持续高渗治疗(20%氯化钠静脉输注≥24小时),402例未接受。颅内高压患者中,持续高渗治疗组90天生存相对风险为1.43(95%CI 0.99-2.06,p=0.05),倾向评分调整后生存风险比为1.74(95%CI 1.36-2.23,p<0.001);90天良好结局(GOS 4-5分)治疗组45.2% vs 未治疗组35.8%(p=0.06)。系统评价纳入8项研究1304例患者,显示持续高渗治疗与ICU内死亡率降低相关(干预组112/474死亡(23.6%)vs 对照组244/781死亡(31.2%);OR 1.42(95%CI 1.04-1.95),p=0.03,I²=15%)。

要点

  • TBI合并颅内高压患者中,持续高渗治疗(20%氯化钠静脉输注≥24小时)与调整后90天生存改善相关(调整HR 1.74,95%CI 1.36-2.23,p<0.001)。
  • 未调整的90天生存相对风险为1.43(95%CI 0.99-2.06,p=0.05),90天良好结局(GOS 4-5分)治疗组45.2% vs 未治疗组35.8%(p=0.06)。
  • 系统评价8项研究1304例患者显示,持续高渗治疗与ICU内死亡率降低相关(干预组23.6% vs 对照组31.2%;OR 1.42,95%CI 1.04-1.95,p=0.03,I²=15%)。
  • 研究纳入标准为格拉斯哥昏迷评分≤12且脑CT有创伤相关病灶的TBI患者,持续高渗治疗方案为20%氯化钠静脉输注持续24小时或以上。

适用人群与场景

  • 创伤性脑损伤患者,格拉斯哥昏迷评分≤12且脑CT显示创伤相关病灶,来自Corti-TC、BI-VILI和ATLANREA三项前瞻性多中心试验数据库。
  • 发生颅内高压的患者(545/1086,51.7%)中,143例接受持续高渗治疗,402例未接受。

诊断标准与关键阈值

  • 持续高渗治疗定义为20%氯化钠静脉输注持续24小时或以上。

处置流程与药物剂量

  • 持续高渗治疗:20%氯化钠静脉输注,持续24小时或以上。

研究设计与关键结果

  • 研究类型:多中心前瞻性队列研究及系统评价;纳入1086例TBI患者,545例(51.7%)发生颅内高压,其中143例接受持续高渗治疗,402例未接受。
  • 主要终点:颅内高压患者90天生存相对风险1.43(95%CI 0.99-2.06,p=0.05);倾向评分调整后生存风险比1.74(95%CI 1.36-2.23,p<0.001)。
  • 次要终点:90天良好结局(GOS 4-5分)治疗组45.2% vs 未治疗组35.8%(p=0.06)。
  • 系统评价:纳入8项研究1304例患者,持续高渗治疗与ICU内死亡率降低相关(干预组112/474死亡(23.6%)vs 对照组244/781死亡(31.2%);OR 1.42(95%CI 1.04-1.95),p=0.03,I²=15%)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列研究及系统评价。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,持续高渗治疗用于创伤后颅内高压与调整后90天生存改善相关,该结果被文献综述强化。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intracranial hypertension (ICH) is a major cause of death after traumatic brain injury (TBI). Continuous hyperosmolar therapy (CHT) has been proposed for the treatment of ICH, but its effectiveness is controversial. We compared the mortality and outcomes in patients with TBI with ICH treated or not with CHT.

METHODS: We included patients with TBI (Glasgow Coma Scale ≤ 12 and trauma-associated lesion on brain computed tomography (CT) scan) from the databases of the prospective multicentre trials Corti-TC, BI-VILI and ATLANREA. CHT consisted of an intravenous infusion of NaCl 20% for 24 hours or more. The primary outcome was the risk of survival at day 90, adjusted for predefined covariates and baseline differences, allowing us to reduce the bias resulting from confounding factors in observational studies. A systematic review was conducted including studies published from 1966 to December 2016.

RESULTS: Among the 1086 included patients, 545 (51.7%) developed ICH (143 treated and 402 not treated with CHT). In patients with ICH, the relative risk of survival at day 90 with CHT was 1.43 (95% CI, 0.99-2.06, p = 0.05). The adjusted hazard ratio for survival was 1.74 (95% CI, 1.36-2.23, p < 0.001) in propensity-score-adjusted analysis. At day 90, favourable outcomes (Glasgow Outcome Scale 4-5) occurred in 45.2% of treated patients with ICH and in 35.8% of patients with ICH not treated with CHT (p = 0.06). A review of the literature including 1304 patients from eight studies suggests that CHT is associated with a reduction of in-ICU mortality (intervention, 112/474 deaths (23.6%) vs. control, 244/781 deaths (31.2%); OR 1.42 (95% CI, 1.04-1.95), p = 0.03, I 2 = 15%).

CONCLUSIONS: CHT for the treatment of posttraumatic ICH was associated with improved adjusted 90-day survival. This result was strengthened by a review of the literature.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Asehnoune K, Lasocki S, Seguin P, et al. Association between continuous hyperosmolar therapy and survival in patients with traumatic brain injury - a multicentre prospective cohort study and systematic review. Crit Care. 2017. PMID: 29282104. doi:10.1186/s13054-017-1918-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。